KRAS and cholangiocarcinoma: One such study (BINGO trial) did not show meaningful improvement in survival with cetuximab in combination with gemcitabine and cisplatin as compared to a placebo in cholangiocarcinoma patients, however, a more recent single arm trial (TACTIC trial) that included only KRAS wild type patients showed a response rate of 46% suggesting a more selected population as a better target 18, 19.